Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Schlemm’s canal outflow pathway consists of the trabecular meshwork, Schlemm’s canal (a circular, endothelium-lined vessel at the corneoscleral junction), and associated collector channels that drain aqueous humor from the anterior chamber of the eye into the venous system[1][3][5]. This pathway is critical for the regulation of intraocular pressure and is the primary conventional drainage route for aqueous humor, accounting for up to 90% of outflow under normal conditions[2][5]. Dysfunction or increased resistance in this pathway, caused by anatomical changes or pathological remodeling, is central to the development of primary open-angle glaucoma and ocular hypertension[1][3][5]. Various drugs and surgical procedures target this pathway—with the aim of reducing outflow resistance and controlling intraocular pressure—to prevent glaucomatous optic nerve damage[2][4].
Enhance aqueous humor outflow through remodeling or dilating Schlemm’s canal and related structures. Reduce resistance at the trabecular meshwork and collector channels. Lower intraocular pressure by facilitating drainage from the anterior chamber.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Schlemm’s canal outflow pathway.